Welcome to our dedicated page for Medpace Holdings news (Ticker: MEDP), a resource for investors and traders seeking the latest updates and insights on Medpace Holdings stock.
Medpace Holdings, Inc. (Nasdaq: MEDP) is a scientifically driven, global, full-service clinical contract research organization (CRO) that regularly issues detailed financial and operational updates. This news page aggregates Medpace news, including quarterly and annual earnings releases, conference call announcements, and other disclosures that matter to investors following MEDP stock and the clinical research sector.
Medpace’s press releases focus on revenue trends, GAAP net income, EBITDA and EBITDA margin, backlog levels, and net new business awards, along with net book-to-bill ratios. The company also provides financial guidance ranges for upcoming periods, discussing expected revenue, net income, and EBITDA, as well as assumptions related to tax rates, interest income, and diluted share counts. These updates help readers understand how demand for Medpace’s Phase I–IV clinical development services is evolving over time.
In addition to earnings results, Medpace frequently announces the dates and times of upcoming earnings releases and conference calls, along with webcast access details and references to supplemental slide presentations in its investors section. The company’s news also touches on capital allocation decisions, such as stock repurchase program authorizations and remaining repurchase capacity, and occasionally on financing arrangements, as reflected in filings related to its unsecured credit facility.
Because Medpace operates as a global CRO serving biotechnology, pharmaceutical and medical device sponsors, its news flow offers insight into the broader outsourcing environment for clinical research and development. Investors, analysts, and industry observers can use this page to review historical announcements, monitor new earnings releases, and track changes in guidance, backlog, and booking trends over time.
Summary not available.
Summary not available.
Summary not available.
Medpace Holdings, Inc. (Nasdaq: MEDP) reported robust financial results for Q1 2023, with revenue of $434.1 million, up 31.2% year-over-year. The company achieved a net book-to-bill ratio of 1.28x, with net new business awards of $555.8 million, a 31.4% increase. GAAP net income rose to $72.9 million or $2.27 per diluted share, compared to $61.3 million or $1.69 per diluted share last year. EBITDA increased 31.9% to $92.8 million, yielding an EBITDA margin of 21.4%. The company projects 2023 revenue between $1.745 billion and $1.805 billion, reflecting growth of 19.5% to 23.6%.
Cash flow from operations reached $80.1 million, with a remaining $332.7 million for share repurchase. Medpace will host a conference call on April 25, 2023, to further discuss these results.
Medpace Holdings (Nasdaq: MEDP) will report its Q1 2023 financial results on April 24, 2023, after market close. A conference call is scheduled for April 25, 2023, at 9:00 a.m. ET to discuss these results. Interested participants can register in advance through a provided link and are encouraged to join 10 minutes early. The call will also be accessible via webcast on Medpace's investor relations website, where a replay will be available afterwards. Additionally, a supplemental slide presentation will be posted on the site prior to the call.
Medpace Holdings, Inc. (Nasdaq: MEDP) reported a 27.7% increase in fourth-quarter 2022 revenue, reaching $394.1 million, compared to $308.6 million in Q4 2021. The net income for Q4 2022 rose to $68.7 million or $2.12 per diluted share, up from $50.0 million or $1.32 per diluted share the previous year. Full-year 2022 revenue was $1,460.0 million, a 27.8% increase. The company forecasts 2023 revenue between $1.690 billion and $1.750 billion, implying growth of 15.8% to 19.9%.
Medpace Holdings, Inc. (NASDAQ: MEDP) will release its fourth quarter and fiscal year 2022 financial results on February 13, 2023, after market close. A conference call is scheduled for February 14, 2023, at 9:00 a.m. ET to discuss these results. Participants can register in advance through the provided link. The call will also be accessible via webcast on Medpace's investor website, with a replay available after the event. Medpace is a global clinical contract research organization offering comprehensive services across various therapeutic areas.
Medpace Holdings, Inc. (NASDAQ: MEDP) reported third-quarter 2022 revenue of $383.7 million, up 29.8% year-over-year. Net new business awards reached $470.9 million, yielding a net book-to-bill ratio of 1.23x. GAAP net income was $66.0 million or $2.05 per diluted share, compared to $48.6 million or $1.29 in Q3 2021, with a net income margin of 17.2%. EBITDA increased 48.5% to $89.3 million. The outlook for 2022 anticipates revenue of $1.440 billion to $1.460 billion.
Medpace Holdings, Inc. (Nasdaq: MEDP) will release its third quarter 2022 financial results after market close on October 24, 2022. A conference call will follow on October 25, 2022, at 9:00 a.m. ET to discuss these results. Interested parties can register here. A supplemental slide presentation will be available in the 'Investors' section of their website.
Medpace Holdings, Inc. (MEDP) reported a revenue of $351.2 million for Q2 2022, a 26.2% increase from $278.3 million a year earlier. Net new business awards rose by 16.3% to $450.6 million, achieving a net book-to-bill ratio of 1.28x. The company posted a GAAP net income of $49.4 million, or $1.46 per diluted share, marking a significant increase from the $39.9 million in Q2 2021. EBITDA climbed 42.0% to $68.1 million, equating to a margin of 19.4%. Medpace forecasts 2022 revenue between $1.405 billion and $1.435 billion.